Is cell death a critical end point for anticancer therapies or is cytostasis sufficient?
about
Lectin of Concanavalin A as an anti-hepatoma therapeutic agentTiming and extent of response in colorectal cancer: critical review of current data and implication for future trialsA critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapyCancer concepts and principles: primer for the interventional oncologist-part IICombination treatment of tamoxifen with risperidone in breast cancerCaspase-8 activation by TRAIL monotherapy predicts responses to IAPi and TRAIL combination treatment in breast cancer cell linesNovel amphiphilic cationic porphyrin and its Ag(II) complex as potential anticancer agents.In vitro viability and cytotoxicity testing and same-well multi-parametric combinations for high throughput screeningEvolving role of Sorafenib in the management of hepatocellular carcinoma.Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.A novel microtubule-modulating agent induces mitochondrially driven caspase-dependent apoptosis via mitotic checkpoint activation in human prostate cancer cells.The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivityInteraction of standardized mistletoe (Viscum album) extracts with chemotherapeutic drugs regarding cytostatic and cytotoxic effects in vitro.A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy.Yang-Dan-Tang, Identified from 15 Chinese Herbal Formulae, Inhibits Human Lung Cancer Cell Proliferation via Cell Cycle Arrest.Selective cytotoxicity of a Vietnamese traditional formula, Nam Dia long, against MCF-7 cells by synergistic effects.Synergistic control of sex hormones by 17β-HSD type 7: a novel target for estrogen-dependent breast cancer.Enhanced anti-tumour effects of Vinca alkaloids given separately from cytostatic therapies.Organometallic Iridium(III) anticancer complexes with new mechanisms of action: NCI-60 screening, mitochondrial targeting, and apoptosis.Early oncology clinical trial design in the era of molecular-targeted agents.Kinesin spindle protein (KSP) inhibitors in combination with chemotherapeutic agents for cancer therapy.Sorafenib use in the transplant setting.Modeling of Patient-Derived Xenografts in Colorectal Cancer.Emulsion technologies for multicellular tumour spheroid radiation assays.A Cytostatic Ruthenium(II)-Platinum(II) Bis(terpyridyl) Anticancer Complex That Blocks Entry into S Phase by Up-regulating p27(KIP1).Simultaneous Interference with HER1/EGFR and RAC1 Signaling Drives Cytostasis and Suppression of Survivin in Human Glioma Cells in Vitro.JLK1486, a N,N-[(8-hydroxyquinoline)methyl]-substituted benzylamine analogue, inhibits melanoma proliferation and induces autophagy.The Multi-Leu peptide inhibitor discriminates between PACE4 and furin and exhibits antiproliferative effects on prostate cancer cells.Screening of Venezuelan medicinal plant extracts for cytostatic and cytotoxic activity against tumor cell lines.Cell cycle-arrested tumor cells exhibit increased sensitivity towards TRAIL-induced apoptosis.Bevacizumab attenuates major signaling cascades and eIF4E translation initiation factor in multiple myeloma cells.Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma.Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs.Galeterone and its analogs inhibit Mnk-eIF4E axis, synergize with gemcitabine, impede pancreatic cancer cell migration, invasion and proliferation and inhibit tumor growth in miceImiquimod Induces Apoptosis in Human Endometrial Cancer Cells In vitro and Prevents Tumor Progression In vivo.In vitro genotoxicity assessment of the synthetic plant growth regulator, 1-naphthaleneacetamide.Therapeutic benefit of radiotherapy in huge (≥10 cm) unresectable hepatocellular carcinoma.Update on in vitro cytotoxicity assays for drug development.Fascaplysin induces caspase mediated crosstalk between apoptosis and autophagy through the inhibition of PI3K/AKT/mTOR signaling cascade in human leukemia HL-60 cells.Mitosis is not a key target of microtubule agents in patient tumors.
P2860
Q21284430-008B87AB-6727-46FE-B119-FC0D97B92979Q26797292-DFB87F70-7B55-455F-8C25-8D4CB51CC96FQ26849503-C37B09E1-5289-4440-B102-566BA6336957Q27010961-2766951C-03D0-4A0B-AB39-C24A84FBE452Q28539274-2E73AA95-09E6-4010-AAE9-906129CE3970Q30398758-3B654CB7-8C3F-4043-9405-68C1DB7BC744Q30660258-B036F836-12DD-4759-8724-7AE760467F25Q33576021-87634AAD-A19D-45A0-B2F1-1FA075B5B39BQ33779864-7336856B-CD76-4D2B-9F34-67AD35C913B8Q33880064-B3ACC37C-09F1-48F9-A44A-2A814734CA13Q33905704-6C3EDE1F-518F-44FB-B5FF-E29453C6C538Q34036041-6DDD4A5F-EA5F-4990-80F6-AB7B1264BE92Q35084512-FD97AEE1-9D97-4C19-AAD9-D617F3B58447Q35677134-30D6669D-C280-4AD6-A4AC-9BE290B49657Q36014834-45E99077-96F6-423F-8288-DC8784FCB121Q36078830-105EB94A-C51E-493F-98CE-51A4D39BB908Q36331426-CD44FBBD-0AD8-42C3-8242-ED502666CE53Q36709220-C6E77363-C76D-41B5-9083-D317681CC4F2Q36952837-180ABBF9-6C43-4142-9B48-FD184EE6C305Q37783623-DF57817D-6752-49DF-8420-6F9FB8DE3839Q38130485-6DB92987-C002-4A89-BB7D-1AB8415081C5Q38210270-DAFE08BA-F8FD-4E06-A6F9-B72FD3D20EF8Q38705019-4C8BAAE1-DF93-49AF-8EC4-184239AAF25AQ38828865-CF7443C0-065F-40AF-A702-F003AE9F1F47Q38878220-08A901E0-17F8-4E46-92E4-2B49423CF212Q38921941-A215C270-062F-4174-91D7-47A30794E8E4Q38964432-800ABBEE-B536-48BC-B0E7-A6107495C37CQ39249464-992F4D0C-4D18-4AEC-B793-CAE1A4BB659CQ39339495-2A5C4C35-7873-4E99-A78B-4F3DCBE53FC1Q39406143-CC1CE5B6-84FF-437E-8046-CE152A149DC0Q39443134-BD28E14D-477A-452D-A28A-A5186B19C549Q39996613-800F8AED-DA60-4676-82C2-F5E0B62E6E95Q40804607-5ED7DD1A-19DA-4CEA-8DA2-497842369287Q41592725-D79A3FD3-8B0E-4AB8-B19F-2D75CE6BFEEAQ41815158-4DD210EC-CE9C-431D-B967-DFE5B0C21510Q42223839-68E800AD-762C-47EE-B2DE-FEE91B8A1A48Q43897398-58B22884-2ECF-449F-9D5A-2B6F2D5079FAQ44748416-13688641-BE6E-4A8F-95A3-F207EDA0F3EEQ52978302-C3064F6F-9978-40EF-89E0-7DF4EF7EC80AQ53271035-F5C6CE51-7A22-4FFE-B50C-0E47334CFD2B
P2860
Is cell death a critical end point for anticancer therapies or is cytostasis sufficient?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Is cell death a critical end point for anticancer therapies or is cytostasis sufficient?
@en
Is cell death a critical end point for anticancer therapies or is cytostasis sufficient?
@nl
type
label
Is cell death a critical end point for anticancer therapies or is cytostasis sufficient?
@en
Is cell death a critical end point for anticancer therapies or is cytostasis sufficient?
@nl
prefLabel
Is cell death a critical end point for anticancer therapies or is cytostasis sufficient?
@en
Is cell death a critical end point for anticancer therapies or is cytostasis sufficient?
@nl
P1476
Is cell death a critical end point for anticancer therapies or is cytostasis sufficient?
@en
P2093
P304
P356
10.1158/1078-0432.CCR-07-2141
P407
P50
P577
2007-12-01T00:00:00Z